TregTherapeutics Inc. is pioneering a transformative approach to treating autoimmune diseases through its TILAC™ platform, which focuses on the induction of immune tolerance. This innovative technology diverges from traditional methods by utilizing a unique formulation that combines a vaccine adjuvant with an anti-inflammatory cytokine. Unlike previous attempts that required the identification and delivery of specific pathogenic antigens, the TILAC™ approach leverages the body's own immune system by creating a tolerogenic microenvironment. This environment encourages regulatory T cells (Tregs) to down-regulate the inflammatory response associated with various autoimmune conditions, promoting immune homeostasis without the need for complex procedures or patient-derived biological contributions.

The TILAC™ platform operates by targeting dendritic cells (DCs), which play a crucial role in the immune response. Under the right conditions, these cells can be induced to generate Tregs instead of triggering an inflammatory response. The mechanism involves the interaction of the cytokine in the TILAC™ formulation with receptors on the DCs, leading to the presentation of endogenous self-antigens in a manner that promotes tolerance. This results in the clonal expansion of Tregs that specifically target the pathogenic antigens driving the disease, effectively quelling inflammation and establishing long-term immune memory. The versatility of this technology holds promise for addressing a wide range of immuno-inflammatory conditions, potentially impacting millions of lives globally.

United States

TregTherapeutics Inc. is a preclinical stage company focused on the treatment and cure of multiple sclerosis. The objective of the TregTherapeutics tolerogenic vaccine is to reverse the inflammatory T cell immune attack in demyelinating lesions of an MS patient, and subsequently, to create an anti-inflammatory tolerogenic response within that patient.

TregTherapeutics Inc.

Company Details